The company that won a years-long patent war just got a check from the loser. The loser’s stock soared. The winner’s barely moved.
Oct 15, 2026
•
9 min read
A manufactured housing REIT near its 52-week low just got a Strong Buy upgrade this morning. Earnings are a week out, and the business keeps executing.
Oct 13, 2026
7 min read
The first approved fatty-liver drug just proved it works across major genetic risk groups. Fair-value models peg it more than 40% above where it trades.
Oct 10, 2026
8 min read
A $45B life sciences monopoly raised guidance, won drugmakers, and the AI product that could reprice everything hasn’t touched the P&L yet.
Oct 8, 2026
Index funds had to dump it. The business didn’t change. Now it yields over 5%, trades near multi-year lows, and earnings are weeks away.
Oct 6, 2026
This stock is still nearly 20% below its 52-week high, even as buybacks continue ahead of November earnings.
Oct 3, 2026
A helicopter franchise sits on the Army’s biggest rotorcraft contract, and earnings in four weeks make this the most compelling setup in the defense space right now.
Oct 1, 2026
A Q2 earnings beat, a Las Vegas portfolio, and a Middle East project that the current stock price ignores make this one of the most asymmetric setups in gaming.
Sep 29, 2026
A failed takeover, a Caesars acquisition, and a reverse bid story that flipped the whole narrative overnight create a specific post-chaos entry point for you today.
Sep 26, 2026
An $8 billion Amazon deal sent this stock soaring—then the market erased the entire move, setting up a critical test next month.
Sep 24, 2026
A completed biosciences spin-off, and a forward multiple that looks cheap against the peer group make this one of the more interesting setups in healthcare right now.
Sep 22, 2026
Three approved medicines, a near-term Phase 3 readout, and an FDA decision eight days away make this one of the busiest catalyst windows in biotech right now.
Sep 19, 2026
Leadership consolidation aimed at driving out costs, plus a consensus pointing to an earnings recovery, make this one worth understanding before the next print.
Sep 17, 2026
The founding-era operator is back, comps have flipped positive for six straight quarters, and a $700 million buyback is starting in the back half of this year.
Sep 15, 2026
A massive Q2 earnings beat, and a forward earnings multiple below the peer group average make this 3M carveout worth understanding before the next catalyst hits.
Sep 12, 2026
This homebuilder is trading below book value just as a shifting rate cycle could give the housing market its next catalyst.
Sep 10, 2026
A clean Phase 3 win in a condition with zero approved treatments, and a freshly loaded balance sheet put this biotech in a genuinely interesting position.
Sep 8, 2026
The billionaire crowd just piled into this power stock while it was still down a third from its highs. That’s not the kind of thing that happens by accident.
Sep 5, 2026
The market keeps hammering this name over weak sales. But its balance sheet looks better by the day, and Wednesday’s bounce could be a sign the tide is turning.
Sep 3, 2026
A biotech just delivered the first successful late-stage trial ever run in its category, and got punished for it. This gap won’t last.
Sep 1, 2026
A company built on sleep medicine just landed a cancer approval that could redraw its growth story, with a valuation that still hasn’t caught up to what the pipeline is worth.
Aug 29, 2026
A diversified wealth platform is growing revenue in double digits, and buying back stock hand over fist, yet trades at a fraction of what comparable US financials command.
Aug 27, 2026
After a brutal reset year, adjusted earnings are forecast to jump in tomorrow’s print, driven by delicious growth, while the stock has run 33% this year.
Aug 25, 2026
A major competitor collapsed, leaving hundreds of valuable locations behind. This beaten-down retailer could be perfectly positioned to take them.
Aug 22, 2026
Organic sales just hit their fastest pace in years, free cash flow margins expanded sharply, and the two fastest-growing brands in the portfolio have barely scratched the surface of their international potential.
Aug 20, 2026
